Corcept Therapeutics Incorporated

BIT:1CORT Stock Report

Market Cap: €8.8b

Corcept Therapeutics Management

Management criteria checks 2/4

Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 27.5 years. total yearly compensation is $15.30M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 2.67% of the company’s shares, worth €235.70M. The average tenure of the management team and the board of directors is 5.7 years and 24.8 years respectively.

Key information

Joseph Belanoff

Chief executive officer

US$15.3m

Total compensation

CEO salary percentage7.73%
CEO tenure27.5yrs
CEO ownership2.7%
Management average tenure5.7yrs
Board average tenure24.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joseph Belanoff's remuneration changed compared to Corcept Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$47m

Dec 31 2025US$15mUS$1m

US$98m

Sep 30 2025n/an/a

US$105m

Jun 30 2025n/an/a

US$132m

Mar 31 2025n/an/a

US$133m

Dec 31 2024US$10mUS$1m

US$140m

Sep 30 2024n/an/a

US$140m

Jun 30 2024n/an/a

US$125m

Mar 31 2024n/an/a

US$117m

Dec 31 2023US$9mUS$1m

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Compensation vs Market: Joseph's total compensation ($USD15.30M) is above average for companies of similar size in the Italian market ($USD6.18M).

Compensation vs Earnings: Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Joseph Belanoff (69 yo)

27.5yrs
Tenure
US$15,303,551
Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder27.5yrsUS$15.30m2.67%
€ 235.7m
Atabak Mokari
CFO & Treasurer5.3yrsUS$6.14m0.015%
€ 1.3m
Sean Maduck
President of Endocrinology10.3yrsUS$6.21m0.11%
€ 9.8m
William Guyer
Chief Development Officer4.9yrsUS$6.34m0.0037%
€ 327.6k
Gary Robb
Chief Business Officer & Secretary12.5yrsUS$6.38m0.094%
€ 8.3m
Joseph Lyon
Chief Technology & Accounting Officer6yrsno data0.0066%
€ 578.4k
Hazel Hunt
Chief Scientific Officer6yrsUS$3.11m0.24%
€ 21.0m
Amy Flood
Chief Human Resources & Communications Officer5yrsno datano data
Monica Tellado
President of Emerging Markets2.7yrsno datano data
Roberto Vieira
President of Oncology2.5yrsno datano data
5.7yrs
Average Tenure
55.5yo
Average Age

Experienced Management: 1CORT's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder27.5yrsUS$15.30m2.67%
€ 235.7m
George Baker
Independent Director27.5yrsUS$768.00k5.17%
€ 456.5m
David Mahoney
Independent Director22yrsUS$784.50k1.15%
€ 101.8m
Charles Nemeroff
Member of Scientific Advisory Boardno datano datano data
James Wilson
Independent Chairman27.5yrsUS$1.29m1.38%
€ 122.1m
Florian Holsboer
Member of Scientific Advisory Boardno datano datano data
Bruce McEwen
Member of Scientific Advisory Boardno datano datano data
Ned Kalin
Member of Scientific Advisory Boardno datano datano data
Edo Kloet
Member of Scientific Advisory Boardno datano datano data
Gregg Alton
Independent Director6.3yrsUS$787.00k0%
€ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno datano datano data
Kimberly Park
Independent Director6.8yrsUS$764.99k0%
€ 0
24.8yrs
Average Tenure
70.5yo
Average Age

Experienced Board: 1CORT's board of directors are seasoned and experienced ( 24.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/29 15:08
End of Day Share Price 2026/07/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corcept Therapeutics Incorporated is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.